Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Coats Disease (COATS-VEGF)
NCT03940690Phase 3Terminated
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in Coats disease, sponsored by Adolphe de Rothschild Foundation Hospital. Started Oct 2019; status: terminated.
02
Drugs
bevacizumab
03
Conditions
Coats disease
Beyond the preview
Go deeper on NCT03940690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940690.